Sponsor name | Trials on EUCTR | Trials due to report results | % Reported | Trials with inconsistent data | Major? |
---|---|---|---|---|---|
Novartis | 1504 | 941 | 100.0% | 277 | major |
GlaxoSmithKline | 1172 | 706 | 100.0% | 351 | major |
Pfizer | 880 | 546 | 99.8% | 207 | major |
Merck Sharp & Dohme (MSD) | 832 | 487 | 100.0% | 176 | major |
Roche | 780 | 388 | 97.7% | 162 | major |
Sanofi S.A. | 737 | 380 | 100.0% | 256 | major |
Astrazeneca | 714 | 398 | 98.7% | 97 | major |
Johnson & Johnson | 554 | 315 | 99.7% | 117 | major |
Eli Lilly | 478 | 303 | 99.7% | 73 | major |
Medical University of Vienna | 424 | 240 | 95.0% | 33 | major |
Bristol-Myers Squibb | 396 | 204 | 100.0% | 80 | major |
Boehringer Ingelheim | 395 | 300 | 100.0% | 40 | major |
Bayer | 336 | 232 | 100.0% | 52 | major |
Hospitals of Paris (AP-HP) | 336 | 49 | 18.4% | 47 | major |
Amgen Inc | 301 | 189 | 100.0% | 47 | major |
Novo Nordisk | 266 | 177 | 100.0% | 33 | major |
Radboud University Medical Centre | 256 | 68 | 48.5% | 38 | major |
Gilead Sciences Inc | 254 | 169 | 100.0% | 51 | major |
Rigshospitalet | 254 | 126 | 40.5% | 23 | major |
Abbvie | 252 | 122 | 99.2% | 45 | major |
KU Leuven | 251 | 123 | 98.4% | 8 | major |
No Sponsor Name Given | 236 | 80 | 63.7% | 22 | major |
UCB | 232 | 121 | 100.0% | 74 | major |
Erasmus University | 230 | 11 | 72.7% | 30 | major |
Takeda | 223 | 142 | 99.3% | 30 | major |
University of Amsterdam | 216 | 19 | 42.1% | 29 | major |
Aarhus University | 212 | 104 | 60.6% | 9 | major |
Charité-Universitätsmedizin Berlin | 208 | 140 | 87.9% | 7 | major |
Agostino Gemelli University Polyclinic | 193 | 13 | 7.7% | 109 | major |
VU University Medical Centre | 182 | 25 | 40.0% | 17 | major |
University of Groningen | 176 | 10 | 50.0% | 11 | major |
Merck KGaA | 175 | 114 | 100.0% | 32 | major |
Utrecht University | 170 | 21 | 42.9% | 42 | major |
Leiden University | 169 | 10 | 50.0% | 15 | major |
University College London | 163 | 90 | 95.6% | 5 | major |
IRCCS Ospedale San Raffaele | 159 | 54 | 100.0% | 9 | major |
Astellas | 154 | 108 | 100.0% | 27 | major |
Servier Laboratories | 151 | 117 | 100.0% | 17 | major |
Allergan | 147 | 101 | 95.0% | 23 | major |
Ghent University | 147 | 56 | 57.1% | 42 | major |
University of Oxford | 146 | 86 | 96.5% | 0 | major |
Imperial College London | 145 | 103 | 94.2% | 1 | major |
Celgene | 143 | 70 | 98.6% | 21 | major |
Karolinska University Hospital | 137 | 21 | 33.3% | 12 | major |
IRCCS Azienda Ospedaliero-Universitaria di Bologna | 135 | 1 | 100.0% | 34 | major |
Medical University of Graz | 134 | 70 | 80.0% | 8 | major |
Novartis Vaccines | 132 | 65 | 100.0% | 63 | major |
Biogen | 131 | 82 | 96.3% | 25 | major |
Eisai Inc. | 128 | 67 | 100.0% | 41 | major |
Helsinki University | 128 | 24 | 45.8% | 9 | major |
Pierre Fabre S.A. | 122 | 97 | 99.0% | 7 | major |
University of Birmingham | 117 | 53 | 100.0% | 5 | major |
Odense University Hospital | 116 | 67 | 89.6% | 14 | major |
Chiesi Farmaceutici S.p.A | 114 | 74 | 100.0% | 18 | major |
Shire | 114 | 64 | 100.0% | 33 | major |
Oslo University Hospital | 111 | 14 | 57.1% | 8 | major |
Abbott | 109 | 87 | 96.6% | 18 | major |
European Organisation for the Research and Treatment of Cancer (EORTC) | 109 | 56 | 94.6% | 16 | major |
Vertex Pharmaceuticals, Inc. | 108 | 55 | 100.0% | 27 | major |
Hospices Civils de Lyon | 108 | 21 | 23.8% | 10 | major |
King’s College London | 107 | 73 | 98.6% | 3 | major |
Herlev and Gentofte Hospital | 104 | 51 | 54.9% | 11 | major |
National Cancer Institute Italy (Istituto Nazionale dei Tumori) | 103 | 4 | 25.0% | 21 | major |
Université libre de Bruxelles | 102 | 16 | 56.2% | 11 | major |
Teva | 96 | 73 | 98.6% | 13 | major |
Actelion Pharmaceuticals Ltd | 96 | 63 | 100.0% | 18 | major |
Ipsen | 92 | 62 | 100.0% | 19 | major |
H. Lundbeck A/S | 89 | 69 | 98.6% | 11 | major |
CSL Behring | 87 | 50 | 100.0% | 25 | major |
Karolinska Institutet | 87 | 27 | 88.9% | 11 | major |
Antoni van Leeuwenhoek Hospital | 86 | 3 | 100.0% | 8 | major |
Unicancer | 84 | 10 | 90.0% | 2 | major |
Daiichi Sankyo | 83 | 48 | 100.0% | 13 | major |
Guy's and St Thomas' NHS Foundation Trust | 82 | 50 | 94.0% | 2 | major |
Regeneron Pharmaceuticals Inc. | 82 | 29 | 100.0% | 24 | major |
Incyte Corporation | 82 | 21 | 95.2% | 12 | major |
Fundació Clínic per a la Recerca Biomèdica | 82 | 6 | 33.3% | 28 | major |
Genentech | 80 | 57 | 100.0% | 8 | major |
University of Munich (Ludwig-Maximilians) | 80 | 46 | 41.3% | 5 | major |
University of Cologne | 80 | 43 | 95.3% | 3 | major |
Innsbruck Medical University | 79 | 41 | 82.9% | 9 | major |
Maastricht University | 79 | 9 | 33.3% | 12 | major |
Otsuka | 78 | 52 | 100.0% | 16 | major |
Alexion Pharmaceuticals, Inc | 78 | 35 | 97.1% | 13 | major |
Alcon | 76 | 44 | 100.0% | 31 | major |
CHU de Toulouse | 76 | 14 | 0.0% | 13 | major |
University of Dundee | 74 | 69 | 100.0% | 1 | major |
University of Leeds | 72 | 52 | 98.1% | 0 | major |
Menarini Group | 71 | 55 | 94.5% | 7 | major |
NHS Greater Glasgow and Clyde | 71 | 40 | 100.0% | 2 | major |
European Institute of Oncology | 70 | 1 | 0.0% | 17 | major |
The Newcastle upon Tyne Hospitals NHS Foundation Trust | 69 | 56 | 92.9% | 1 | major |
LEO Pharma A/S | 69 | 52 | 100.0% | 5 | major |
Galderma R&D | 68 | 50 | 100.0% | 3 | major |
Technical University of Munich | 68 | 43 | 97.7% | 11 | major |
Bispebjerg Hospital | 67 | 37 | 51.4% | 7 | major |
Vall d'Hebron University Hospital | 67 | 17 | 82.4% | 16 | major |
Vrije Universiteit Brussel | 67 | 7 | 71.4% | 7 | major |
ACCORD (University of Edinburgh & NHS Lothian) | 66 | 44 | 93.2% | 1 | major |
University Hospital Tübingen | 66 | 31 | 80.6% | 2 | major |
Queen Mary University of London | 65 | 42 | 100.0% | 4 | major |
Heidelberg University Hospital | 65 | 35 | 74.3% | 2 | major |
Baxter | 64 | 49 | 95.9% | 8 | major |
Hospital de la Santa Creu i Sant Pau | 64 | 12 | 58.3% | 12 | major |
University of Nottingham | 63 | 57 | 100.0% | 1 | major |
Manchester University NHS Foundation Trust | 63 | 53 | 100.0% | 0 | major |
CHU Clermont-Ferrand | 63 | 11 | 0.0% | 7 | major |
Mario Negri Institute | 62 | 25 | 100.0% | 13 | major |
University of Turku | 62 | 13 | 61.5% | 2 | major |
Almirall S.A. | 60 | 49 | 100.0% | 6 | major |
The Royal Marsden NHS Foundation Trust | 60 | 29 | 82.8% | 2 | major |
University Erlangen-Nuremberg | 60 | 29 | 82.8% | 3 | major |
CHU de Bordeaux | 59 | 11 | 18.2% | 10 | major |
Gothenburg University | 59 | 9 | 55.6% | 10 | major |
Ferring Pharmaceuticals | 58 | 50 | 100.0% | 5 | major |
Cliniques Universitaires Saint-Luc | 58 | 15 | 93.3% | 13 | major |
HOVON Foundation | 58 | 3 | 0.0% | 5 | major |
Policlinico San Matteo | 57 | 4 | 0.0% | 35 | major |
University Hospitals of Leicester NHS Trust | 56 | 45 | 95.6% | 5 | major |
Hvidovre Hospital | 56 | 28 | 21.4% | 5 | major |
Belfast Health and Social Care Trust | 55 | 45 | 82.2% | 1 | major |
Mundipharma | 55 | 45 | 93.3% | 4 | major |
Hannover Medical School | 55 | 37 | 21.6% | 11 | major |
University of Hamburg | 54 | 23 | 82.6% | 1 | major |
Skåne University Hospital | 54 | 12 | 41.7% | 4 | major |
Octapharma AG | 53 | 32 | 100.0% | 15 | major |
The Lymphoma Study Association (LYSA) | 53 | 18 | 83.3% | 2 | major |
AOU Policlinico di Modena | 53 | 5 | 20.0% | 24 | major |
King's College Hospital NHS Foundation Trust | 52 | 41 | 95.1% | 1 | major |
Barts Health NHS Trust | 51 | 44 | 97.7% | 4 | major |
Johannes Gutenberg University of Mainz | 51 | 34 | 58.8% | 5 | major |
BioMarin Pharmaceutical Inc | 51 | 21 | 81.0% | 11 | major |
University Hospital Southampton NHS Foundation Trust | 51 | 20 | 65.0% | 2 | major |
Cambridge University Hospitals NHS Foundation Trust | 50 | 41 | 92.7% | 1 | major |
RWTH Aachen University | 50 | 29 | 82.8% | 11 | major |
University of Freiburg | 50 | 25 | 64.0% | 2 | major |